John F. Sheridan

Career

1. 2019 – now
   Tandem Diabetes Caresrc
   President & CEO; director since June 2019
   Succeeded Kim Blickenstaff, who became Executive Chairman, effective 2019-03-01
2. 2013 – 2019
   Tandem Diabetes Caresrc
   EVP & Chief Operating Officer
   Joined April 2013, before the November 2013 IPO
3. 2012 – 2013
   Rapiscan Systems, Inc.src
   Chief Operating Officer (March 2012 to February 2013)
4. 2004 – 2010
   Volcano Corporationsrc
   EVP, Research & Development and Operations (November 2004 to March 2010)
5. 2002 – 2004
   CardioNet, Inc.src
   EVP, Operations (May 2002 to May 2004)
6. 1998 – 2002
   Digirad Corporationsrc
   VP, Operations (March 1998 to May 2002)

Not located: 2010-03 to 2012-03 (between Volcano and Rapiscan) and 2004-05 to 2004-11 are not described in any filing searched; everything before 1998 not located

Achievements

• Ran operations at Tandem from April 2013, through the IPO, and has been CEO since March 2019src
• Tandem passed $1bn of annual sales in 2025 ($1.015bn), with a record 58% gross margin in Q4 2025 and a first positive quarterly operating margin since 2021src
• Asked the compensation committee to move about $300k of his $3m 2025 LTI target to other executives to cut stock-based pay and burn ratesrc
• Bought 10,000 shares in the open market at about $10.23 on 2025-08-11, four days after the stock fell on the t:slim X2 speaker correctionsrc
• Say-on-pay passed with 97.3% of votes cast for and against at the May 2026 meetingsrc

Education

• University of West Florida, BS Chemistrysrc
• Boston University, MBA Business Administrationsrc

Background

• Family He and the CFO, Leigh Vosseller, are in a personal relationship and share a primary residence. She reports directly to him; the board knew before he became CEO in 2019, neither sets the other's pay, and the audit committee added internal controls. The proxy lists no other family relationshipssrc
• Boards Director of Acutus Medical, Inc. from March 2021 to April 2025src
• Legal Named defendant with the CFO in Lowe v. Tandem Diabetes Care (S.D. Cal., filed 2023-09-08) over 2022 sales trends and forecasts. Dismissed with leave to amend on 2024-04-29, then with prejudice on 2024-06-04; two derivative suits naming him were voluntarily dismissed in July 2024src
• Legal A law firm posted a 2025 securities class action complaint over the t:slim X2 speaker correction (class period 2024-08-01 to 2025-08-07). This pass did not confirm the defendants or the status in a primary document; the Q2 2026 10-Q reports no proceeding with a probable or estimable material losssrc
• Other The proxy reports no Item 401(f) legal proceedings for any director or executive officersrc